Cover Image
市場調查報告書

全球癌症免疫療法市場:查核點抑制劑

The Global Immuno-oncology Therapeutics Market - Checkpoint Inhibitors

出版商 Frost & Sullivan 商品編碼 363924
出版日期 內容資訊 英文 127 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症免疫療法市場:查核點抑制劑 The Global Immuno-oncology Therapeutics Market - Checkpoint Inhibitors
出版日期: 2016年07月04日 內容資訊: 英文 127 Pages
簡介

本報告提供全球癌症免疫療法市場上查核點抑制劑的開發平台(管線)調查分析,正在開發的企業·產品,成本·償付的影響,商業化的課題,市場機會等,提供著有系統的資訊。

第1章 摘要整理

第2章 創新的開發平台分析

  • 主要的手法與範圍
  • 查核點抑制劑的藥物分類
  • 查核點產品核可的時間軸
  • 競爭情形:標的市場區隔,上市/開發中產品數
  • 查核點區分 (各子類型)
  • 競爭情形:標靶產品數 (各階段)

第3章 競爭情形

  • 查核點開發平台(各企業,標的,階段)
  • 查核點標的區分
  • 競爭情形:CTLA-4/CAIX/GITR
  • 競爭情形:LAG-3
  • 競爭情形:TIM-3

第4章 主要查核點抑制劑的產品開發動態即時看板系統

  • PD-1 產品開發動態即時看板系統
  • PD-L1 產品開發動態即時看板系統
  • CTLA-4 產品開發動態即時看板系統
  • PD-L1 產品開發動態即時看板系統

第5章 主要企業值得注意的產品 (各標的)

  • 現有企業的競爭概要
  • 查核點抑制劑:PD-1/PD-L1
  • PD-L1 產品開發動態即時看板系統
  • 查核點抑制劑:CTLA-4
  • CTLA-4 產品開發動態即時看板系統

第6章 聯合治療的機會

  • 癌症免疫聯合治療
  • 查核點並用臨床試驗:各適應症
  • 值得注意的癌症免疫檢查點相位3
  • 該領域上創新的技術與進步

第7章 商業化分析

  • 市場機會
  • 創新的治療的可能性
  • 整體環境影響要素
  • 查核點產品的專利到期

第8章 商業化分析:生物標記

第9章 商業化分析:成本的問題

第10章 商業化分析:主要企業與值得注意的產品

第11章 商業化分析:資金的問題

第12章 結論與要點

第13章 附錄

第14章 關於Frost&Sullivan

目錄
Product Code: MBA0-01-00-00-00

The Next Generation of Cancer Therapies

Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.

Key Questions this Study will Answer

  • What checkpoint therapies are in development and for what indications?
  • What products and indications will be launched in the next 5 years?
  • Who is investing in the development of checkpoint inhibitors, at what phase, and at what level of deal funding?
  • What are some of the cost implications for checkpoint therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of checkpoint inhibitors?
  • What challenges do payers face related to the high cost of specialty therapeutics?

Table of Contents

1. EXECUTIVE SUMMARY-CHECKPOINT INHIBITORS

  • 1. Scope and Segmentation
  • 2. Key Questions this Study will Answer
  • 3. Key Takeaways
  • 4. Market Snapshot
  • 5. Market Snapshot (continued)
  • 6. 8 Big Market Themes for Checkpoint Inhibitors
  • 7. A Vibrant Ecosystem
  • 8. Paradigm Expansion to Solid Tumor Cancer Therapies
  • 9. Regional Launch Highlights
  • 10. Game-changing Companies
  • 11. Significant Investor Funding
  • 12. Key 2016 Predictions-Checkpoint Inhibitor Market

2. DISRUPTIVE PIPELINE ANALYSIS

  • 1. Key Methodology and Scope
  • 2. Checkpoint Inhibitor Drug Classes
  • 3. Timeline of Checkpoint Product Approvals
  • 4. Competitive Landscape-Target Segments, Count of Marketed and Pipeline Products
  • 5. Checkpoint Segmentation by Subtype
  • 6. Competitive Landscape-Target Product Counts by Phase

3. COMPETITIVE LANDSCAPE

  • 1. Checkpoint Pipelines by Company, Target, and Phase
  • 2. Checkpoint Pipelines by Company, Target, and Phase (continued)
  • 3. Checkpoint Pipelines by Company, Target, and Phase (continued)
  • 4. Checkpoint Pipelines by Company, Target, and Phase (continued)
  • 5. Checkpoint Target Segmentation
  • 6. Competitive Landscape-CTLA-4/CAIX/GITR Segment, Products in Development
  • 7. Competitive Landscape-PD-1/PD-L1 (programmed death 1-receptor)
  • 8. Competitive Landscape-LAG-3 (lymphocyte activating gene 3)
  • 9. Competitive Landscape-TIM-3 (T-cell immunoglobin and mucin domain 3)

4. PRODUCT DASHBOARDS OF LEADING CHECKPOINT INHIBITORS

  • 1. PD-1 Product Dashboard-Keytruda® (Pembrolizumab): Merck & Co. (Marketed)
  • 2. PD-1 Product Dashboard-Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)
  • 3. CTLA-4 Product Dashboard-Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)
  • 4. PD-L1 Product Dashboard-Tecentriq® (Atezolizumab): Roche (Marketed)

5. KEY COMPANIES AND PRODUCTS TO WATCH BY TARGET

  • 1. Competitive Overview of Established Companies
  • 2. Checkpoint Inhibitors-PD-1/PD-L1
  • 3. PD-L1 Product Dashboard-Avelumab (MSB0010718C): Merck KGaA (Phase III)
  • 4. PD-L1 Product Dashboard-Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)
  • 5. Checkpoint Inhibitors-CTLA-4
  • 6. CTLA-4 Product Dashboard-Tremelimumab (MEDI-1123): AstraZeneca (Phase III)

6. OPPORTUNITIES IN COMBINATION THERAPIES

  • 1. Immuno-oncology Combination Therapies
  • 2. Checkpoint Combination Clinical Trials by Indication
  • 3. Immuno-oncology Checkpoint Phase III Trials to Watch
  • 4. Immuno-oncology Checkpoint Phase III Trials To Watch (continued)
  • 5. Disruptive Technologies and Advances in this Field

7. COMMERCIALIZATION ANALYSIS

  • 1. Market Opportunities
  • 2. Potential Game-changing Therapies
  • 3. Overall Environmental Impact Factors
  • 4. Checkpoint Product Patent Expirations

8. COMMERCIALIZATION ANALYSIS-BIOMARKERS

  • 1. Biomarker Challenges

9. COMMERCIALIZATION ANALYSIS-COST CONSIDERATIONS

  • 1. Opportunities in this Market-Escalating Drug Costs
  • 2. Checkpoint Inhibitor Payer Environment
  • 3. J-Codes, Annual Costs, and US Payers
  • 4. Reimbursement Pathway-On-label Reimbursement Path
  • 5. Reimbursement Pathway-Off-Label, Medicare
  • 6. Reimbursement Pathway-Off-Label, Commercial Payers
  • 7. Reimbursement Pathway-Off-Label, Commercial Payers (continued)
  • 8. A Snapshot of Global Drug Price Control Methods
  • 9. Pitfalls to Avoid

10. COMMERCIALIZATION ANALYSIS-KEY COMPANIES AND PRODUCTS TO WATCH

  • 1. Companies to Watch
  • 2. Companies to Watch (continued)
  • 3. Checkpoint Inhibitor Forecast Sales Total-2020 ($20.5B)Actual Sales by Product

11. COMMERCIALIZATION ANALYSIS-FUNDING CONSIDERATIONS

  • 1. Investors Pour in Significant Funds
  • 2. Checkpoint Milestones
  • 3. 2015 Deal and Financing-CTLA-4 Receptor Gene Therapy
  • 4. 2015 Deal and Financing Summary-PD-1/PD-L1
  • 5. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 6. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 7. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 8. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 9. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 10. 2015 Deal and Financing Summary-PD-1/PD-L1 (continued)
  • 11. 2015 Deal and Financing Summary-LAG-3
  • 12. 2015 Deal and Financing Summary-LAG-3 (continued)
  • 13. 2015 Deal and Financing Summary-LAG-3 (continued)
  • 14. 2015 Deal and Financing Summary-TIM-3

12. CONCLUSION AND TAKE HOME POINTS

  • Conclusion and Take Home Points
  • 1. Key Conclusions
  • 2. Growth Opportunities in 4 Checkpoint Inhibitor Segments
  • 3. New Market Opportunities-Checkpoint Inhibitors
  • 4. The Last Word-3 Big Predictions
  • 5. Legal Disclaimer

13. APPENDIX-CHECKPOINT INHIBITORS DEVELOPMENT PIPELINE SUMMARIES

  • 1. Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development
  • 2. Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development (continued)
  • 3. Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development (continued)
  • 4. Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development (continued)
  • 5. Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development (continued)
  • 6. Pipeline Analysis-LAG-3 Products in Development
  • 7. Pipeline Analysis-LAG-3 Products in Development (continued)
  • 8. Pipeline Analysis-LAG-3 Products in Development (continued)
  • 9. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development
  • 10. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 11. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 12. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 13. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 14. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 15. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 16. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 17. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 18. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 19. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 20. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 21. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 22. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 23. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 24. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 25. Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development (continued)
  • 26. Pipeline Analysis-TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development
  • 27. Pipeline Analysis-TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)
  • 28. Pipeline Analysis-TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)

14. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
Back to Top